Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients

Myasthenia gravis (MG) is an autoimmune disorder generally mediated by antibodies against the acetylcholine receptors (AChR) of the skeletal muscles. CD4 T cells help B cells to produce antibodies through their production of cytokines or chemokines. In this study, we evaluated the frequency of regulatory (Treg) and IL-17 producing CD4 T-cell subsets (Th17) in peripheral blood mononuclear cells (PBMCs) of patients with MG. The transcription factor, forkhead transcription factor (Foxp3), is essential for T-cell regulatory function, and the orphan nuclear receptor, RORγT, is important in Th17 cell differentiation. In MG patients, Foxp3 mRNA expression in PBMCs was lower than those in healthy subjects (p = 0.007), while there was no significant difference of RORγT mRNA expression between MG patients and healthy subjects. Glucocorticoid-induced tumour-necrosis-factor receptor-related protein (GITR) is expressed predominantly on CD4+CD25+ Treg cells. We found that the number of GITR+CD4+CD25+ T cells in peripheral lymphocytes in MG patients was lower than that in healthy subjects (P < 0.01). In addition, there was a significant positive correlation between the change of the frequency of GITR+CD4+CD25+ T cells and the changing rate in quantitative myasthenia gravis scores (%) (p = 0.03). Furthermore, there was a significant negative correlation between the change of the percentage of GITR+CD4+CD25+ T cells (% lymphocytes) and the changing rate of daily PSL doses (%) (P = 0.002). The relative RORγT levels in PBMCs negatively correlated with the Th1/Th2 ratio in CD4+ cells in MG patients (p = 0.014). In conclusion, our findings suggest that Th17 cells affect the production of autoantibodies through their influence on the Th1- and Th2-cytokine balance in PBMCs of MG patients. On the other hand, Treg cells are suggested to be involved in the clinical condition or severity of MG disease.